标题
An update on long-acting agents in HIV therapy
作者
关键词
-
出版物
Future Virology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2023-10-26
DOI
10.2217/fvl-2023-0097
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
- (2023) Tahilin Sanchez Karver et al. AIDS PATIENT CARE AND STDS
- Long acting cabotegravir and rilpivirine: innovation, new challenges and opportunities
- (2023) Josep M Llibre et al. CLINICAL INFECTIOUS DISEASES
- Updating the Adherence–Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Preexposure Prophylaxis Among Cisgender Women
- (2023) Peter L Anderson et al. CLINICAL INFECTIOUS DISEASES
- Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
- (2023) Mark A. Marzinke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
- (2023) Chloe Orkin et al. CLINICAL INFECTIOUS DISEASES
- Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
- (2023) Isabella C. Young et al. Nature Communications
- Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
- (2023) Sharana Mahomed et al. Lancet HIV
- Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya
- (2023) Sammy Gakero Gachigua et al. Frontiers in Reproductive Health
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
- (2023) Moti N Ramgopal et al. Lancet HIV
- Impact of Integrase Sequences From HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
- (2022) Jerry L. Jeffrey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention
- (2022) Sharana Mahomed et al. JOURNAL OF INFECTIOUS DISEASES
- Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
- (2022) Henning Gruell et al. Lancet Microbe
- Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- (2022) Tracy L. Diamond et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance
- (2022) Ming-Tain Lai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
- (2022) Sinead Delany-Moretlwe et al. LANCET
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
- (2022) Sorana Segal-Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
- (2022) Jérémy Dufloo et al. Nature Communications
- Broadly neutralizing antibodies against HIV-1 and concepts for application
- (2022) Henning Gruell et al. Current Opinion in Virology
- The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions
- (2022) Stefano Rusconi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis
- (2022) Fabiana Volpe-Zanutto et al. JOURNAL OF CONTROLLED RELEASE
- Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
- (2022) Paul Thoueille et al. Pharmaceutics
- Lenacapavir: First Approval
- (2022) Julia Paik DRUGS
- HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention
- (2022) Susan H Eshleman et al. JOURNAL OF INFECTIOUS DISEASES
- Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
- (2022) Jesper D. Gunst et al. NATURE MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection
- (2022) Randolph P. Matthews et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
- (2022) Samir K Gupta et al. Lancet HIV
- Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
- (2022) Lise Jamieson et al. Lancet HIV
- A qualitative study on the acceptability of and adherence to a vaginal ring for HIV prophylaxis among adolescent girls
- (2021) Zoë Baker et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study
- (2021) Annalene Nel et al. Lancet HIV
- Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
- (2021) Jared M Baeten et al. Lancet HIV
- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants
- (2021) Elizabeth J McFarland et al. JOURNAL OF INFECTIOUS DISEASES
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
- (2021) Lawrence Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
- (2021) Raphael J. Landovitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
- (2021) Denise C. Hsu et al. Frontiers in Immunology
- Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week
- (2021) Dirk Schürmann et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naïve adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine
- (2021) J.-M. Molina et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
- (2021) Kathryn E. Stephenson et al. NATURE MEDICINE
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
- (2020) Dirk Schürmann et al. Lancet HIV
- Clinical targeting of HIV capsid protein with a long-acting small molecule
- (2020) John O. Link et al. NATURE
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
- (2020) Silvia Bertagnolio et al. JOURNAL OF INFECTIOUS DISEASES
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Microneedle array systems for long-acting drug delivery
- (2020) Lalit K. Vora et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
- (2019) Alison J Rodger et al. LANCET
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Trevor A Crowell et al. Lancet HIV
- Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
- (2019) Yehuda Z. Cohen et al. PLoS One
- Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
- (2019) S. Rahima Benhabbour et al. Nature Communications
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
- (2019) Martin R Gaudinski et al. Lancet HIV
- HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis
- (2018) Ravindra K Gupta et al. LANCET INFECTIOUS DISEASES
- Ultra-long-acting removable drug delivery system for HIV treatment and prevention
- (2018) Martina Kovarova et al. Nature Communications
- Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
- (2016) Andrew Owen et al. ADVANCED DRUG DELIVERY REVIEWS
- HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
- (2016) Johannes F. Scheid et al. NATURE
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
- (2016) Katharine J. Bar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
- (2016) Annalene Nel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
- (2016) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies
- (2015) Cadi Irvine et al. CLINICAL INFECTIOUS DISEASES
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
- (2015) Jeanne M. Marrazzo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
- (2015) Jean-Michel Molina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
- (2015) Rebecca M. Lynch et al. Science Translational Medicine
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
- (2014) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
- (2013) Brian A. Johns et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preexposure Prophylaxis for HIV Infection among African Women
- (2012) Lut Van Damme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor
- (2009) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now